Login
$ARTV
$4.27 -$1.89 (30.68%) Close

Company Executives

$ARTV Management Team

Dr. Heather Raymon

Senior Vice President - Research and Early Development

Age 60
Compensation -
Sex Female

Dr. Brian Daniels

Independent Chairman of the Board

Age 66
Compensation $42.74K USD
Sex Male

Dr. Fred Aslan

President

Chief Executive Officer

Director

Age 50
Compensation $7.828M USD
Sex Male

Mr. Christopher Horan

Chief Technical Operations Officer

Age 58
Compensation $726.9K USD
Sex Male

Ms. Jennifer Bush

Chief Operating Officer

Chief Legal Officer

Corporate Secretary and Compliance Officer

Age 50
Compensation $1.506M USD
Sex Female

Dr. Subhashis Banerjee

Chief Medical Officer

Age 68
Compensation -
Sex Male

Mr. Thad Huston

Chief Financial Officer

Age 56
Compensation -
Sex Male
Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
3.6 years
from year joined
CEO also chairs the board
No
Brian Daniels, M.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Brian Daniels, M.D.
67 2020
6 years
Independent
Clinical Development Committee · Chair Compensation Committee · Chair
CSL Ltd. $117,357
Laura Stoppel, Ph.D.
40 2020
6 years
Independent None stated Acumen Pharmaceuticals, Inc. $71,249
Elaine Sorg
59 2026
0 years
Independent
Audit Committee Commercial Planning Committee · Chair
CSL Limited Not stated
Daniel Baker, M.D.
75 2025
1 year
Independent
Compensation Committee Clinical Development Committee Commercial Planning Committee Nominating and Corporate Governance Committee · Chair
Shattuck Labs, Inc. $180,527
Fred Aslan, M.D.
52 2021
5 years
Not stated None stated None stated Paid as CEO
Elizabeth Hougen
65 2021
5 years
Independent
Audit Committee · Chair
None stated $71,390
Alison Moore, Ph.D.
59 2024
2 years
Independent None stated None stated $71,390

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

9 disclosed in the proxy filed Aug 3, 2026
GC Corp. and its affiliate
holder of more than 5% of our capital stock, or entities affiliated with them
$ 5,614,424

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
5AM Ventures VI, L.P. and its affiliate
holder of more than 5% of our capital stock, or entities affiliated with them
$ 4,709,212

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
venBio Global Strategic Fund III, L.P.
holder of more than 5% of our capital stock, or entities affiliated with them
$ 4,709,212

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
RA Capital Healthcare Fund, L.P. and its affiliate
holder of more than 5% of our capital stock, or entities affiliated with them
$ 4,709,212

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
Venrock Healthcare Capital Partners EG, L.P. and its affiliate
holder of more than 5% of our capital stock, or entities affiliated with them
$ 3,689,300

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
GC Cell
owner of more than 5% of our outstanding capital stock at the time of execution of the Manufacturing Agreement; affiliated with directors Yu-Kyeong Hwang, Ph.D. and Yong-Jun Huh
$2.9 million and $3.7 million
2024 and 2023

Master Manufacturing Agreement under which we incurred manufacturing-related costs.

With Company Open in proxy
GC Cell
owner of more than 5% of our outstanding capital stock at the time of execution of the AB-201 Agreement; affiliated with directors Yu-Kyeong Hwang, Ph.D., Yong-Jun Huh and James Park
$0.3 million

AB-201 Selected Product License Agreement under which we paid a one-time upfront fee to GC Cell.

With Company Open in proxy
Blackbird Clinical, Inc.
entity controlled by RA Capital, which owned more than 5% of our outstanding capital stock; Laura Stoppel, Ph.D., a member of our Board, is affiliated with RA Capital
Zero and $0.3 million
2025 and 2024

Services agreement under which Blackbird provides consulting services for our clinical trials.

With Blackbird Clinical, Inc. Open in proxy
Carnot Pharma, LLC
entity controlled by RA Capital, which owned more than 5% of our outstanding capital stock; Laura Stoppel, Ph.D., a member of our Board, is affiliated with RA Capital
$31 thousand and $15 thousand
2025 and 2024

Services agreement under which Carnot provides consulting services for our clinical trials.

With Carnot Pharma, LLC Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support